MedTrace Logo

Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis

NCT03204721 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2025-09-24

No results posted yet for this study

Summary

The main aim is to test the preventive use of extracorporeal photophoresis (ECP) against development of graft-versus-host disease (GVHD) in patients undergoing allogeneic stem cell transplantation for hematological malignancy.

Conditions

  • Graft-Versus-Host Disease

Interventions

OTHER

Extracorporeal photophoresis (ECP)

The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Geir E Tjønnfjord, Prof,MD,PhD · Oslo University Hospital HF, Department of Haematology Rikshospitalet

  • Per Ole Iversen, Prof,MD,PhD · Oslo University Hospital HF, Department of Haematology Rikshospitalet

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2021-04-30
Completion
2021-04-30

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03204721 on ClinicalTrials.gov